بچپن کے دماغی ٹیومر منشیات کی نشوونما میں ایک بڑی پیشرفت ہے۔ بچوں میں دماغی ٹیومر ایک عام طور پر مہلک بیماری ہے۔ حالیہ تحقیق سے پتہ چلا ہے کہ ایک نئی کاک ٹیل دوا بچپن کے دماغی ٹیومر کا علاج کر سکتی ہے۔
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain ٹیومر each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common مہلک ٹیومر of the cerebellum. This دماغ کی رسولی grows rapidly and most often occurs in children around the age of 5. علاج کے اختیارات include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastoma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive نیوروبلاسٹوما. In laboratory tests, the drug killed کینسر cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
دوسری دوائیوں کے ساتھ ملا کر ، نئے مرکبات جو ٹیومر کو روکتے ہیں ان کو وٹرو میں اور ویوو میں دکھایا جاتا ہے۔
کلینکل ٹرائلز for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
اگر ہم ٹیومر جینوں پر مبنی ٹیلر سے تیار کردہ علاج تیار کرسکتے ہیں جس کی حکمت عملی کو عام طور پر انفرادی نوعیت کا علاج کہا جاتا ہے تو یہ کچھ مخصوص ٹیومر والے مریضوں کے لئے ایک بہت بڑی خوشخبری لاسکتی ہے۔
نیوروبلاسٹوما کی چار مختلف اقسام ہیں ، اور ٹیومر کے تیسرے گروپ کے مریضوں میں بدترین تشخیص ہوتا ہے. صرف 40٪ مریض طویل عرصے تک زندہ رہتے ہیں۔ اس کے برعکس ، دوسرے نیوروبلاسٹوماس کی طویل مدتی بقا نسبتا optim امید مند ہے ، اور 80٪ مریض طویل عرصے تک زندہ رہ سکتے ہیں۔
نیوروبلاسٹوما کے مریضوں کے بیشتر تیسرے گروپ میں ایم وائی سی آنکوجین کا زیادہ اظہار ہوتا ہے ، جو بے قابو سیل ڈویژن اور ٹیومر کی تشکیل کا سبب ہے۔
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s میڈیکل سینٹر واشنگٹن ڈی سی میں
The most effective of these compounds is panobinostat, which has entered clinical trials in other کینسر کی اقسام, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block کینسر سیل بقا
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
